Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

This study has been completed.
Sponsor:
Information provided by:
BZL Biologics
ClinicalTrials.gov Identifier:
NCT00040586
First received: July 1, 2002
Last updated: January 19, 2007
Last verified: July 2002
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given